Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

SCAA Puts the 'AED' in CPR/AED Week to Make Communities Safer, Better Equipped to Respond to Cardiac Arrest

June 1, 2011 12:32 pm | by Bio-Medicine.Org | News | Comments

WASHINGTON, June 1, 2011 /PRNewswire-USNewswire/ -- For 30 years, the national survival rate of sudden cardiac arrest (SCA) has remained a low six percent. Recognizing the need for expanded awareness of the public health crisis of SCA, the Sudden Cardiac Arrest Association (SCAA) is...

Legs 4 Life, LLC Acquires Venosan North America

June 1, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

ASHEBORO, N.C., June 1, 2011 /- Legs 4 Life, LLC, the parent company of Ames Walker International , proudly announced today that it has acquired Venosan North America, Venosan's American brand and distributorship of Venosan's Swiss made stockings.  The acquisition enables Legs 4 Life...

Alexion lands FDA priority review for blood clotting drug target

June 1, 2011 10:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Alexion Pharmaceuticals Inc. has won priority review from the U.S. Food and Drug Administration for its supplemental Biologics License Application for the company's drug candidate Soliris to treat atypical Hemolytic Uremic Syndrome.

Advertisement

Argos Therapeutics' Arcelisâ„¢ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlat...

June 1, 2011 5:32 am | by Bio-Medicine.Org | News | Comments

DURHAM, N.C., June 1, 2011 /- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The...

Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets

June 1, 2011 5:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, June 1, 2011 /-Reportlinker.com announces that a new market research report is available in its catalogue: Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets...

Reportlinker Adds Cardiovascular Monitoring and Diagnostic Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

June 1, 2011 3:31 am | by Bio-Medicine.Org | News | Comments

NEW YORK, June 1, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Cardiovascular Monitoring and Diagnostic Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017...

HeartSine® Increases AED System Warranty to Longest in the Industry

May 31, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

NEWTOWN, Pa., May 31, 2011 /- HeartSine Technologies, Inc, a world leader in personal and public access defibrillators, has increased its system warranty period to an exclusive 10 years on its popular HeartSine ® samaritan ® PAD 300P Public Access Defibrillator (PAD) for the...

Vicor Technologies' CEO David H. Fater to Present Live, Online at RetailInvestorConferences.com

May 27, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

BOCA RATON, Fla., May 27, 2011 /- Vicor Technologies, Inc. (OTCBB: VCRT) today announced that CEO David H. Fater will present at RetailInvestorConferences.com.   Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative,...

Advertisement

A Blood Test for Depression

May 26, 2011 8:32 pm | by Massachusetts Institute of Technology | News | Comments

A commercial test could let doctors easily screen for major depressive disorder.

Kensey Nash Announces New Unsecured Revolving Credit Facility

May 26, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

EXTON, Pa., May 26, 2011 /- Kensey Nash Corporation (Nasdaq: KNSY ) announced today that it has entered into a new $35 million unsecured revolving credit facility with Wells Fargo Bank, National Association. The new credit facility has a term of three years, maturing on May 25, 2014, with...

Kensey Nash to Present at the Jefferies 2011 Global Healthcare Conference

May 26, 2011 10:34 am | by Bio-Medicine.Org | News | Comments

EXTON, Pa., May 26, 2011 /- Kensey Nash Corporation (Nasdaq: KNSY ) is scheduled to present at the Jefferies 2011 Global Healthcare Conference at The Grand Hyatt in New York, on Tuesday, June 7, 2011. Joseph W. Kaufmann, Kensey Nash's President and CEO, will deliver the Company's...

Genzyme to sell $3.8M in Abiomed shares

May 26, 2011 8:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Genzyme Corp. plans to sell 200,000 of the shares it holds in Abiomed Inc., according to a regulatory document Genzyme filed on Wednesday – a stake worth $3.8 million at Abiomed's Wednesday closing price.

Transgenomic, Inc. Acquires Exclusive Worldwide License to Predictive Markers for Cancer Drug Response

May 26, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

OMAHA, Neb., May 26, 2011 /- Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's (Bronx, NY, US) patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including...

Advertisement

Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss

May 26, 2011 2:31 am | by Bio-Medicine.Org | News | Comments

ISTANBUL, May 26, 2011 /- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on Obesity. The analyses show that lorcaserin caused statistically significant...

Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly

May 25, 2011 10:32 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 26, 2011 /- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN ) ("Amylin" or "the Company") today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company (NYSE: LLY ) ("Lilly")...

Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug

May 25, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif. and LONDON, May 25, 2011 /- Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm – have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug,...

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

May 25, 2011 3:33 am | by Boston Scientific | News | Comments

Boston Scientific becomes the first and only company to offer two distinct drug-eluting stents to treat small vessels

KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain

May 24, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

NORTH LIBERTY, Iowa, May 24, 2011 /- KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of its most advanced opioid-based drug candidate, KP201, a novel hydrocodone prodrug for treating pain.  KP201 is a new chemical entity (NCE) composed of hydrocodone...

Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

May 24, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 24, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017...

FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration

May 23, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

TARRYTOWN, N.Y. May 23, 2011 /- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that it has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee Meeting to be held on June 17, 2011 to...

CardioGenics to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc.

May 23, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, May 23, 2011 /- CardioGenics Holdings Inc. (CGNH: OTCB) announced today that Dr. Yahia Gawad, CEO of CardioGenics will be presenting at the 7th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc.  The conference will be held on...

Aethlon Medical to Present the Aethlon ADAPTâ„¢ System at C21 BioVenturesâ„¢ Life Sciences Partnering Conference

May 23, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 23, 2011 / PRNewswire / -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD ), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a...

Your Wireless Healthcare Provided By PulseOximetersPlus

May 23, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

ROCKVILLE, Md., May 23, 2011 /- The healthcare and computing industries rely heavily on mobility. For the past decade, the healthcare industry has been adopting new technologies allowing medical professionals and patients to be more mobile. New medical devices strive to meet these...

CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle

May 23, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

ATLANTA, May 23, 2011 /- CardioMEMS, Inc ., an Atlanta-based medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced that its founder and CEO, Jay Yadav, M.D., was presented with a...

FDA approves Incivek for hepatitis C

May 23, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., May 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading